Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: Synthesis and biological evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 15, 2006, Pages 3906-3912

  Micheli, Fabrizio ^a   Pasquarello, Alessandra ^a   Tedesco, Giovanna ^a   Hamprecht, Dieter ^a   Bonanomi, Giorgio ^a   Checchia, Anna ^a   Jaxa Chamiec, Albert ^b   Damiani, Federica ^a   Davalli, Silvia ^a   Donati, Daniele ^a   Gallotti, Chiara ^a   Petrone, Marcella ^a   Rinaldi, Marilisa ^a   Riley, Graham ^b   Terreni, Silvia ^a   Wood, Martyn ^b  

^a GSK   (Italy)

^b NFSP   (United Kingdom)

Author keywords

5 HT; 5 HT2C; 7 TM; Pharmacophore; Serotonin

Indexed keywords

2 PYRROLIDONE DERIVATIVE; PYRROLE DERIVATIVE;

ANXIETY; ARTICLE; BINDING AFFINITY; DEPRESSION; DRUG POTENCY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

MODELS, MOLECULAR; PYRROLES; PYRROLIDINONES; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS;

EID: 33745125776     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.034     Document Type: Article

References (27)

1. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., and Humphrey P.P.A. Pharmacol. Rev. 46 (1994) 157
2. Humphrey P.P.A., Hartig P., and Hoyer D. Trends Pharmacol. Sci. 14 (1993) 233
3. Nelson D.L. Med. Chem. Res. 3 (1993) 306
4. Baxter G., Kennett G., Blaney F., and Backburn T. Trends Pharmacol. Sci. 16 (1995) 105
5. Kahn R.S., and Wetzler S. Biol. Psychiatry 30 (1991) 1139
6. Bromidge S.M., Dabbs S., Davies D.T., Davies S., Duckworth D.M., Forbes I.T., Gaster L.M., Ham P., Jones G.E., King F.D., Mulholland K.R., Saunders D.V., Wyman P.A., Blaney F.E., Clarke S.E., Blackburn T.P., Holland V., Kennett G.A., Lightowler S., Middlemiss D.N., Trail B., Riley G.J., and Wood M.D. J. Med. Chem. 43 (2000) 1123
7. Kennett G.A., Lightowler S., De Biasi V., Stevens N.C., Wood M.D., Tulloch I.F., and Blackburn T.P. Neuropharmacology 33 (1994) 1581
8. Palvimaki E.P., Roth B.L., Majasuo H., Laakso A., Kuoppamaki M., Syvalahti E., and Hietala J. Psychopharmacology 126 (1996) 234
9. Ni Y.G., and Miledi R. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2036
10. Quested D.J., Sargent P.A., and Cowen P.J. Psychopharmacology 133 (1997) 305
11. Kennaway D.J., and Moyer R.W. Brain Res. 806 (1998) 257
12. Moreau J.-L., Boes M., Jenck F., Martin J.R., Mortas P., and Wichmann J. Eur. Neuropsychopharmacol. 6 (1996) 169
13. Di Giovanni G., De Deurwaerdere P., Di Mascio M., Di Matteo V., Esposito E., and Spampinato U. Neuroscience 91 (1999) 587
14. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. Neuropharmacology 37 (1998) 265
15. Millan M.J., Dekeyne A., and Gobert A. Neuropharmacology 37 (1998) 953
16. Reavill C., Kettle A., Holland V., Riley G., and Blackburn T.P. Br. J. Pharmacol. 126 (1999) 572
17. Kalkman H.O. Life Sci. 54 (1994) 644
18. Fox S.H., Moser B., Brotchie, and Jonathan M. Exp. Neurol. 151 (1998) 35
19. Gaster, L. M.; Wyman, P. A.; Mulholland, K. R.; Davies, D. T. WO 9623769, 1996.
20. Gaster, L. M.; Wyman, P. A.; Mulholland, K. R.; Davies., D. T.; Duckworth, D. M.; Forbes, I. T.; Jones, G. E. WO 9623783, 1996.
21. Bromidge, S. M.; Lovell, P. J.; Moss, S. F.; Serafinowska, H. T. WO 20010809, 2002.
22. Bromidge, S. M.; Lovell, P. J.; Goodacre, C. WO 20030107, 2003.
23. Catalyst 4.6, Accelrys Inc.
24. Bonanomi, G.; Hamprecht, D.; Micheli, F.; Terreni, S. WO 2004089897, 2004.
25. Swain C.G., and Lupton E.C. J. Am. Chem. Soc. 90 (1968) 4328
26. Hansch C., Leo A., Unger S.H., Kim K.H., Nikaitani D., and Lien E.J. J. Med. Chem. 16 (1973) 1207
27. The research complied with national legislation and with company policy on the Care and Use of Animals and with related codes of practice.